Michael Jaharis

• Co-founder, Member of the Board of Directors, Arisaph Pharmaceuticals, Inc.
• Founder, Chairman Emeritus, Kos Pharmaceuticals, Inc.
• Co-Founder, President & Chief Executive Officer, Key Pharmaceuticals, Inc.
• Vice President & Director of the Ethical Drug Division, Miles Laboratories
• Trustee Emeritus, Tufts University
• Chairman of the Board of Overseers, Tufts University School of Medicine
• Member of the Board, Columbia University Medical Center, Weill Cornell Medical College and Graduate School of Medical Sciences
• JD, DePaul University; BA, Carroll College

Kevin Ferro, Managing Director

• Chairman, Arisaph Pharmaceuticals, Inc.
• Member of the Board of Directors, Kos Pharmaceuticals, Inc.
• Chief Executive Officer and Chief Investment Officer, Oikos Advisors LLC
• Chief Executive Officer and Chief Investment Officer, Ferro Capital LLC
• Global Head of Alternative Investments, Commerzbank AG
• Vice President, D. E. Shaw & Co, LP
• BA, Harvard University

Sundar Kodiyalam, Managing Director

• Senior Vice President, Corporate Development & New Business Opportunities, Kos Pharmaceuticals, Inc.
• Vice President, Commercial Development, Ortec International
• Director of Business Development & Licensing, Schering-Plough
• International and US Product Management, Novartis
• MS (Pharmaceutical Administration), Ohio State University; BS (Pharmacy), Madras University

Lyn Baranowski, Vice President

• Director, US Brand Management, Novartis Pharmaceuticals
• Director, US Business Development & Licensing, Novartis Pharmaceuticals
• Senior Policy Advisor, Novartis International
• International Trade Analyst, Dewey Ballantine LLP & US Department of Commerce
• MBA, Harvard Business School; BA, American University

David Smith, Associate

• Senior Associate, Portfolio & Risk Management, Ferro Capital LLC
• Analyst, Transfer Pricing Practice, Ernst & Young
• BA, Harvard University

Christopher Burden, Chief Operating Officer

• Chief Operating Officer, Oikos Advisors LLC
• Chief Operating Officer, Ferro Capital LLC
• Head of Alternative Investment Product Structuring, Commerzbank AG
• Associate Attorney, Asset Management Group, Shearman & Sterling LLP
• JD, American University; BA, Cornell University

Michael Allen, Chief Financial Officer

• Chief Financial Officer, Oikos Advisors LLC
• Director and Operating Committee Member, GlobeOp Financial Services
• Vice President and Controller, UBS, North America & London Equities Divisions
• Managing Consultant, Price Waterhouse London, Capital Market Group
• CICA, Canadian Institute of Chartered Accountants
• MBA, York University, Toronto; BA, Queens University, Kingston

Lawrence B. Copperman, Legal Advisor

• Attorney, Steven K. Aronoff, PC
• Associate Attorney, Gallet Dreyer & Berkey
• Associate Attorney, Lindenbaum & Young
• JD, Georgetown University; BA, Brandeis University